In this case, the technology was improved based upon the surprising discovery that the TAPBPR chaperone acts catalytically on MHC-I-placeholder peptide complexes to create peptide receptive MHC-I species.
Technology is identical to that described in 2018-408-0, except that the ratio of TAPBPR to MHC-I-placeholder peptide complex is less than 1:1. As low as a 1:10,000 ratio of TAPBPR to MHC-I placeholder peptide can be used without an effect on the overall reaction time.
Peptide receptive MHC-I multimer reagents
Identifying antigenic peptides
Identifying and purifying T cell populations
Improved cost effectiveness of making MHC Class I reagents because less of the TAPBPR component needs to be made.
Additional patent claims close off potential loophole in coverage
|European Patent Office||Published Application||EP 4 136 098||02/22/2023||2020-284|
|European Patent Office||Published Application||4085069||11/09/2022||2019-975|
|European Patent Office||Published Application||4085068||11/09/2022||2020-297|
|European Patent Office||Published Application||402841.2||07/20/2022||2020-251|
|United States Of America||Published Application||20210371499||12/20/2021||2020-284|
Additional Patents Pending
MHC-I, Class I MHC, Antigenic Peptide, Peptide Receptive MHC, MHC multimers, MHC tetramers, MHC reagents, Major Histocompatability Complex, Class I, Chaperone, TAPBPR, Catalytic TAPBPR